ACE-031 – 1mg Peptide

ACE-031 (1mg) — Research Compound

ACE-031 is a soluble fusion protein that acts as a decoy receptor for myostatin and other ligands in the transforming growth factor-beta (TGF-β) superfamily. By binding to these ligands before they can attach to the ActRIIB receptor, ACE-031 effectively inhibits the signalling pathways that naturally limit muscle growth. It is studied primarily for its potential to increase muscle mass and strength by removing the biological “brakes” on myogenic development.

Findings from early-stage clinical trials have reported:

• Increases in lean body mass of approximately 1kg observed in healthy subjects following a single dose
  
• Improved muscle volume and cross-sectional area reported via MRI imaging in experimental models
  
• Alterations in bone mineral density markers noted, suggesting a cross-link between muscle and bone signalling
  
• Dose-dependent decreases in serum adiponectin levels observed during the research period
  

Researchers study ACE-031 to investigate the physiological impact of myostatin inhibition on physical performance and metabolic health. It serves as a specialised tool for understanding how the modulation of the TGF-β pathway can influence muscle wasting conditions and neuromuscular disorders. Its unique mechanism of action makes it a focal point for research into the biological limits of hypertrophy and strength gain.

Available Formats:
This compound is available as a vial of lyophilised powder, or can be ordered in a disposable pen, a reusable pen, or a cartridge for an existing reusable pen system.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use